Table 2.
Univariate and multivariate Cox proportional hazard models for OS.
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR | P-value | HR | P-value | |
| PS ≥ 1 | 1.91 (1.17–3.12) | 0.0055* | 1.10 (0.56–2.13) | 0.7835 |
| Age ≥ 71 (years) | 2.60 (1.61–4.15) | < 0.0001* | 2.83 (1.57–5.08) | 0.0005* |
| cT ≥ 3 | 1.57 (0.95–2.57) | 0.0700 | ||
| cN1 ( +) | 2.52 (1.54–4.12) | 0.0002* | 2.47 (1.25–4.88) | 0.0089* |
| Hb ≥ 13.1 (g/dL) | 0.59 (0.36–0.95) | 0.0229* | 0.56 (0.32–0.98) | 0.0422* |
| PSADT < 10 (months) | 2.75 (1.66–4.56) | < 0.0001* | ||
| PSADT < 6 (months) | 2.26 (1.19–4.31) | 0.0128* | ||
| PSADT < 4.65 (months) | 3.16 (1.94–5.14) | < 0.0001* | 2.96 (1.65–5.32) | 0.0003* |
| PSA ≥ 3.3 (ng/dL) | 1.76 (1.12–2.74) | 0.0132* | 0.84 (0.47–1.51) | 0.5625 |
| NHT vs. Vintage | 1.10 (0.71–1.72) | 0.6562 | ||
NHT novel hormonal therapy, cN1 clinical positive pelvic lymph nodes metastasis, cT stage clinical T stage, Hb hemoglobin, HR hazard ratio, OS overall survival, PS performance status, PSA prostate specific antigen, PSADT PSA doubling time, Vintage vintage androgen receptor antagonist.
*P < 0.05.